Early steroid withdrawal therapy in renal transplant recipients: A steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol

Clinical Transplantation

Volumn 21, Issue 1, 2007, Pages 101-109

  Jaber, James J ^a   Feustel, Paul J ^a   Elbahloul, Ossama ^a   Conti, Alexander D ^a   Gallichio, Michael H ^b   Conti, David J ^b,c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ALBANY MEDICAL CENTER   (United States)

^c Section of Transplantation A 6IGE   (United States)

Author keywords

Early steroid withdrawal; Immunosuppression; Renal transplantation

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATOVAQUONE; CALCINEURIN INHIBITOR; CHOLESTEROL; COTRIMOXAZOLE; CREATININE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCELE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; POLYOMA VIRUS; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SURVIVAL TIME; VIRUS INFECTION; WEIGHT GAIN; WOUND DEHISCENCE; WOUND INFECTION;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCINEURIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 33846680173     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00613.x     Document Type: Article

References (33)

1. Barry JM. Renal transplantation. Curr Opin Urol 1999: 9: 121.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004: 351: 2715.
3. Starzl TE. The mystique of organ transplantation. J Am Coll Surg 2005: 201: 160.
4. Strazl TE, Marchioro TC, Waddell WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963: 117: 385.
5. Fryer JP, Granger DK, Levanthal JR et al. Steroid-related complications in the cyclosporin era. Clin Transplant 1994: 8: 224.
6. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocosteroids. Pharmacol Ther 2002: 96: 23.
7. Rhen T, Cidlowski JA. Antiflammatory action of glucocosteroids - new mechanism for old drugs. N Engl J Med 2005: 353: 1711.
8. Hill MN, Grossman RA, Feldman HI et al. Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis 1999: 17: 512.
9. Hirick DE, O'Toole MA, Schulak JA et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis. J Am Soc Nephrol 1993: 4: 1300.
10. Kasiske BL, Chakkera HA, Louis TA et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 200: 11: 1910.
11. Matas MJ, Hrick DE et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Transplantation 1999: 68: 1865.
12. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts; the Canadian Multi-center Transplant Study Group. CMAJ 1992: 147: 645.
13. Matas AJ, Ramcharan T, Parakevas S et al. Rapid discontinuation of steroids in living donor kidney transplantation: A pilot study. Am J Transplant 2001: 1: 278.
14. Shapiro R, Jordan ML, Scantlebury VP et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 1998: 30: 1375.
15. Grinyo JM, Gil-Vernet S, Seron D et al. Steroid withdrawal in mycophenolate mofetil-treated renal allograft recipients. Transplantation 1997: 15: 1688.
16. Matas AJ, Kandaswamy R et al. Prednisone-free maintenance immunosuppression - a 5-year experience Am J Transplant 2005: 5: 2473.
17. Porayko MK, Textor SC, Krom RA et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994: 69: 105.
18. de Mattos AM, Olyaei AJ, Bennet WM. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000: 35: 333.
19. Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donor kidneys. Am J Transplant 2005: 5: 757.
20. Cecka JM, Cook DJ. Optimal use of cadaver donor kidneys: High-risk donors and low-risk recipients. Transplant Proc 1989: 21: 1417.
21. Matas AJ, Gillingham KJ, Humar A et al. Immunologic and nonimmunologic factors: Different risks for cadaver and living donor transplantation. Transplantation 2000: 69: 54.
22. Giral-Classe M, Hourmant M, Cantarovich C et al. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998: 54: 972.
23. Butler JA, Roderick P, Mullee M et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004: 77: 769.
24. Smith AY, Van BC, Lewis RM et al. Factors determining renal transplant outcome at the University of Texas at Houston. Clin Transpl 1987: 155.
25. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003: 42: 1206.
26. Pearson TA, Bazzarre TL, Daniels SR et al. AHA guidelines for primary preventCon of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atheroscleroti vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002: 106: 388.
27. Pearson TA, Blair SN, Daniels SR et al. American Heart Association guide for improving cardiovascular health at the community level: A statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003: 107: 645.
28. Gjertson DW, Terasaki PI, Cecka JM. Impact analysis: A method for evaluating the impact of factors in clinical renal transplantation. Clin Transpl 1998: 437.
29. Escobar FS, Isenberg AL, Conti DJ. Sirolimus immunotherapy: The Albany Medical Center experience. Transplant Proc 2003: 35: 109S.
30. Stevens J, Cai J, Pamuk ER et al. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998: 338: 1.
31. Calle EE, Thun MJ, Petrelli ER et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999: 341: 1097.
32. Wei M, Kampert JB, Barlow CE et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA 1999: 282: 1547.
33. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 1999: 69: 373.